MedTrace Logo

Dextenza for Post-operative Treatment of Pterygium

NCT04351737 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-05-25

No results posted yet for this study

Summary

DEXTENZA for the Treatment of Post-Surgical Pain and Inflammation Compared to Standard of Care Topical Cortico-steroid Treatment in Patients who Undergo Bilateral Pterygium Surgery

Conditions

  • Pterygium of Both Eyes

Interventions

DRUG

Intracanalicular Dexamethasone, (0.4 mg) Insert

To determine post-surgical resolution of pain and inflammation outcomes with DEXTENZA compared to topical steroid treatment in patients who undergo bilateral pterygium surgery.

DRUG

Prednisolone Acetate

To reduce post-surgical pain and inflammation in patients who undergo bilateral pterygium surgery.

Sponsors & Collaborators

  • Brandon Eye Associates, PA

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-15
Primary Completion
2022-07-15
Completion
2023-05-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04351737 on ClinicalTrials.gov